Neuberger Berman Group LLC reduced its holdings in Pfizer Inc. (NYSE:PFE) by 8.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,309,579 shares of the biopharmaceutical company’s stock after selling 695,922 shares during the period. Neuberger Berman Group LLC owned approximately 0.13% of Pfizer worth $238,953,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also bought and sold shares of the company. WFA of San Diego LLC purchased a new position in Pfizer during the second quarter worth about $269,000. Handelsbanken Fonder AB acquired a new stake in shares of Pfizer during the second quarter valued at about $45,508,000. Sequoia Financial Advisors LLC increased its position in shares of Pfizer by 16.8% during the second quarter. Sequoia Financial Advisors LLC now owns 91,533 shares of the biopharmaceutical company’s stock valued at $2,993,000 after acquiring an additional 13,140 shares during the last quarter. Asset Dedication LLC increased its position in shares of Pfizer by 8.0% during the second quarter. Asset Dedication LLC now owns 37,199 shares of the biopharmaceutical company’s stock valued at $1,220,000 after acquiring an additional 2,751 shares during the last quarter. Finally, Cypress Capital LLC acquired a new stake in shares of Pfizer during the second quarter valued at about $998,000. 69.08% of the stock is currently owned by hedge funds and other institutional investors.
Shares of PFE stock traded down $0.02 during trading hours on Wednesday, hitting $36.94. 764,366 shares of the company were exchanged, compared to its average volume of 29,486,596. The firm has a market cap of $205.38 billion, a PE ratio of 14.69, a PEG ratio of 2.91 and a beta of 0.67. Pfizer Inc. has a 1 year low of $27.88 and a 1 year high of $40.97. The company has a quick ratio of 1.16, a current ratio of 1.42 and a debt-to-equity ratio of 0.78. The firm has a fifty day moving average of $37.79 and a 200 day moving average of $35.69.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.64 by $0.14. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The business had revenue of $11.80 billion for the quarter, compared to analyst estimates of $11.55 billion. During the same period in the prior year, the firm posted $0.80 EPS. The company’s revenue was down 11.0% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.89 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 1st. Investors of record on Friday, July 31st were issued a $0.38 dividend. The ex-dividend date was Thursday, July 30th. This represents a $1.52 annualized dividend and a yield of 4.11%. Pfizer’s payout ratio is 51.53%.
In other Pfizer news, Director Ronald E. Blaylock purchased 13,000 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The shares were purchased at an average price of $38.55 per share, for a total transaction of $501,150.00. Following the completion of the acquisition, the director now owns 4,000 shares of the company’s stock, valued at approximately $154,200. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.08% of the company’s stock.
A number of brokerages have weighed in on PFE. Royal Bank of Canada set a $43.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, September 9th. Barclays dropped their price objective on shares of Pfizer from $37.00 to $35.00 in a report on Monday, June 1st. JPMorgan Chase & Co. dropped their price objective on shares of Pfizer from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Monday, June 1st. TheStreet upgraded shares of Pfizer from a “c+” rating to a “b” rating in a report on Monday, June 1st. Finally, UBS Group lifted their price objective on shares of Pfizer from $37.00 to $39.00 and gave the company a “neutral” rating in a report on Wednesday, July 29th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $39.61.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.